• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

    12.26 +0.98 (+8.69%)
    Streaming Delayed Price Updated: 2:41 PM EDT, Sep 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 60,418
    Open 11.13
    Bid (Size) 12.54 (200)
    Ask (Size) 12.75 (100)
    Prev. Close 11.28
    Today's Range 11.13 - 12.89
    52wk Range 4.210 - 23.25
    Shares Outstanding 24,887,446
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Lexaria Receives USD$2.6 Million Tax Rebate Payment
    From Lexaria Bioscience Corp.
    Via ACCESS Newswire
    News headline image
    Lexaria Receives USD$2.6 Million Tax Rebate Payment
    Lexaria’s 2025 Australian human study results in a USD$2.6 million cash rebate 
    Via TheNewswire.com

    Performance

    YTD
    +25.0%
    +25.0%
    1 Month
    +158.1%
    +158.1%
    3 Month
    +32.6%
    +32.6%
    6 Month
    +15.1%
    +15.1%
    1 Year
    -7.7%
    -7.7%

    More News

    Read More
    News headline image
    DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
    From Lexaria Bioscience Corp.
    Via ACCESS Newswire
    News headline image
    Lexaria Enters a Material Transfer Agreement With PegBio
    From Lexaria Bioscience Corp.
    Via ACCESS Newswire
    News headline image
    Lexaria Announces Effective Date for Reverse Stock Split
    From Lexaria Bioscience Corp.
    Via ACCESS Newswire
    News headline image
    Lexaria Updates Business Development
    From Lexaria Bioscience Corp.
    Via ACCESS Newswire
    News headline image
    Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
    From Lexaria Bioscience Corp.
    Via ACCESS Newswire
    News headline image
    Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
    From Lexaria Bioscience Corp.
    Via ACCESS Newswire
    News headline image
    GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
    From Lexaria Bioscience Corp.
    Via ACCESS Newswire
    News headline image
    Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
    Via ACCESS Newswire
    News headline image
    Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
    Via ACCESS Newswire
    News headline image
    Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
    Via ACCESS Newswire
    News headline image
    Lexaria Bioscience Releases Second Episode of Investor Video Series
    Via ACCESS Newswire
    News headline image
    Lexaria Updates Progress on Human Study #7
    Via ACCESS Newswire
    News headline image
    Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
    Via ACCESS Newswire
    Wednesday's session: top gainers and losers ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
    Via ACCESS Newswire
    News headline image
    Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
    Via ACCESS Newswire
    News headline image
    Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
    Via ACCESS Newswire
    News headline image
    Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
    Via ACCESS Newswire
    News headline image
    Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
    Via ACCESS Newswire
    News headline image
    Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
    Via TheNewswire.com
    News headline image
    Lexaria to Begin New Human Clinical Study in GLP-1
    Via ACCESS Newswire
    News headline image
    Lexaria's Robust Patent Portfolio Continues to Grow
    Via ACCESS Newswire

    Frequently Asked Questions

    Is Lexaria Bioscience Corp. - Common Stock publicly traded?
    Yes, Lexaria Bioscience Corp. - Common Stock is publicly traded.
    What exchange does Lexaria Bioscience Corp. - Common Stock trade on?
    Lexaria Bioscience Corp. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Lexaria Bioscience Corp. - Common Stock?
    The ticker symbol for Lexaria Bioscience Corp. - Common Stock is LEXX on the Nasdaq Stock Market
    What is the current price of Lexaria Bioscience Corp. - Common Stock?
    The current price of Lexaria Bioscience Corp. - Common Stock is 12.26
    When was Lexaria Bioscience Corp. - Common Stock last traded?
    The last trade of Lexaria Bioscience Corp. - Common Stock was at 09/01/26 02:41 PM ET
    What is the market capitalization of Lexaria Bioscience Corp. - Common Stock?
    The market capitalization of Lexaria Bioscience Corp. - Common Stock is 305.12M
    How many shares of Lexaria Bioscience Corp. - Common Stock are outstanding?
    Lexaria Bioscience Corp. - Common Stock has 305M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.